top of page
Targeting drug-resistant cell states to overcome standard therapy resistance
Lumaros is currently developing the targeted therapy of choice in NRAS mutant melanoma
Non-genetic plasticity of cancer cells allows adaptation and resistance formation against current therapies
Lumaros is developing novel drug classes that target resistant cancer cell states
bottom of page